PO-0757: The use of Failure Mode Effect Analysis (FMEA) to enhance quality in a busy radiotherapy setting  by Kelly, C. et al.
2nd ESTRO Forum 2013   S285 
 
 POSTER: CLINICAL TRACK: HEALTH ECONOMICS  
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Purpose/Objective: Historically, breast-conservation therapy 
consisted of lumpectomy followed by 6–7 weeks of whole-breast 
radiation therapy (WBRT). More recently, alternatives to WBRT have 
been evaluated. These include hypofractionated WBRT, and partial-
breast irradiation (PBI) through external-beam, brachytherapy, or 
intraoperative RT (IORT). We evaluated the direct cost associated to 
the different RT options. 
Materials and Methods: We performed a cost analysis among: (1) 3-
dimensional conformal RT (3DCRT) using a conventional fractionation 
(33 sessions [25 for the whole breast and 8 for the boost]); (2) 
Hypofractionated 3DCRT (23 sessions [15 for the whole breast and 8 
for the boost]); (3) PBI delivered using: 3DCRT, high and low dose rate 
brachytherapy (HDR and LDR, respectively) and intraoperative RT 
(IORT). Treatment costs included: fractions number, hospitalization 
(i.e. LDR brachytherapy), consults (initial consult and weekly visits 
during treatment; nurse consults; anesthesiologist if needed), 
radiological examinations (i.e. portal verification films, planning 
computed tomography scan), blood tests, and dosimetry calculation. 
No costs were considered for systemic tretaments, post-RT follow-up, 
transportation, accommodation, or meals. Prices of treatment and 
patient support were obtained from the last update of the authorized 
regional government agencies (BOJA 210; October 2005) at regular 
official prices. According the Spanish Association for Health Economy, 
the prices were updated until 2012 increasing the 3% per year to the 
total amount calculated. 
Results: The duration of radiation treatments were 7 and 5 weeks for 
the conventional fractionation and the hypofractionated 3DCRT, 
respectively. Radiation was given in 1 week for the PBI delivered by 
3DCRT or HBR brachytherapy, and 2 days and 1 day when using LDR 
brachytherapy and IORT, respectively.Treatment cost for conventional 
fractionation 3DCRT was 6.518,81€, whereas the hypofractionated 
regimen using the same technology cost was 4.737,76€. PBI costs were 
3.078,60€, 4.483,49€, 4.075,36€, and 7.418,46€ for 3DCRT, LDR 
















Fractions 3679,22€ 2564,30€ 1115,00€ 2368,50€ 2368,50€ 5584,53€ 
Hospitalization    495,59€   
Consults 917,93€ 640,07€ 555,72€ 391,98€ 555,72€ 168,70€ 
Radiological
examinations 
479,96€ 424,58€ 609,18€ 166,14€ 166,14€ 55,38€ 
Dosimetry
calculation 
223,28€ 223,28€ 223,28€ 223,28€ 223,28€ 223,28€ 
 
Conclusions: PBI treatment administration appears to be the more 
economic option, being the 3DCRT the cheapest technique. This 
treatment modality seems to be more convenient for elderly patients, 
especially in situations of difficult access to treatment delivering 
facilities. Multidisciplinary teams offering breast conservation to 
women with early-stage breast cancer should consider accelerated 
radiation regimens offering comparable therapeutic benefit with use 
of fewer Public Health Care Euros. 
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Purpose/Objective: To evaluate the feasibility of comprehensive 
evaluation of emerging Radiation Therapy (RT) innovations. This 
report presents the survey results of Radiation Oncology (RO) 
Physicians' views in regards to the current evaluation process that is 
performed prior to the widespread implementation of RT innovations. 
Materials and Methods: An online survey in English language was sent 
via e-mail to RO Department Heads of randomly selected centers to 
represent North/South American, European, African, Asian and 
Australian centers with a request to forward it to their RO Physicians. 
The survey questionnaire consisted of 20 questions and was created 
using the QuestionPro Online Software. Statistical analysis was done 
using Banner/Pivot Tables and Cross-Tabulation of different variables. 
P-values were calculated using Pearson's Chi-Squared Test. This survey 
report represents the first phase of this project. During the second 
phase, an evaluation protocol software using Head and Neck module 
will be generated and sent online with a feedback questionnaire to be 
reviewed by RO's from various international cancer centers. 
Results: The online survey was viewed by 143 respondent. 121 
respondent have completed the survey (84.62% Completion Rate). The 
majority (39%) were RO Physicians with 5 or more years of practice 
and 81.8% were from academic centers. 60% of respondents think that 
emerging RT technology innovations currently are not appropriately 
evaluated prior to widespread implementation. Also, 82% think that 
there should be a mandate to have more comprehensive evaluation 
prior to widespread implementation of these innovations. 83.5% think 
that vendors should be invited to provide logistical support to such 
comprehensive evaluation process. Years of experience were the only 
statistically significant variable (P-value=0.004) in regards to the 
respondents' views toward the current evaluation process. 71% of 
Junior and 54% of Senior RO Residents think that the current 
evaluation process is appropriate versus 28% of Senior RO Staffs, 33% 
Junior RO Staffs and 25% RO Fellows. The surveyed potential 
advantages/disadvantages of the proposed comprehensive mandatory 
evaluation process are available to be presented at the conference 
along with the evaluation protocol database entry points. 
Conclusions: While we should not in any way hamper creativity and 
innovations of Radiation Therapy Technology, we should strive for 
rigorous standardized post-marketing evaluation of any promising 
innovation prior to its widespread implementation. Any mandatory 
post-marketing comprehensive evaluation process should be carefully 
performed aiming to avoid slowing down such innovations or 
increasing its costs. This will help to reach the target goals of 
improving patients care and the utilization of healthcare resources 
without slowing down RT innovations or increasing their cost. The 
second phase of this project includes creating a software that takes 
these considerations into account.  
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Purpose/Objective: Delivering on quality in radiotherapy is a complex 
task. Colleagues, patients, administrators and tax payers seek 
continual quality improvement. Such demands require radiotherapy 
professionals to be committed to constantly enhancing the service 
they provide. The drive to provide safer, more effective, more 
efficient and more timely services is the goal of the modern 
radiotherapy clinic. Failure Mode Effect Analysis (FMEA) is a technique 
of systems engineering borrowed from large scale industrial processes. 
Its use in radiotherapy has recently been championed by ICRP 112 and 
by the formation of a task group of the American Association of 
Physicists in Medicine (AAPM TG 100). The application of FMEA in a 
clinical radiotherapy environment is described in this work. The 
objective is to assess the effectiveness of FMEA for achieving quality 
improvement in radiotherapy.  
Materials and Methods: Using the conventional FMEA methodology 
this project consisted of four distinct steps as follows: 
1) Process Mapping - a detailed process map was assembled by 
multidsiciplinary team. This map identified 9 distinct nodes and over 
100 sub-nodes of activity which detailed the radiotherapy process 
from initial imaging to first treatment.  
2) Identification of Failure Modes (FM) - comprehensive analysis of 
where the process could fail based on a detailed analysis of the 
process map. 
3) Quantification of FM - risk rating of FM's by analysis of their 
severity, probability of occurrence, and level of detectability. This 
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step uses the Risk Priority Number (RPN) which is a product of relative 
indices of occurrence, detectability and severity. 
4) Corrective re-design - process re-engineering to remove stresses 
from the system and reduce the likelihood of recurrence.  
Results: A complex process map was produced and over 40 potential 
FM's were identified in the system. RPN analysis identified 11 FM's 
which were rated sufficiently highly to initiate corrective re-design. 
This involved major initiatives such as ensuring the process was 
completely paperless, conduction of staff training sessions to promote 
independent checking and the purchase of additional equipment to 
reduce the incidence of incorrect patient set up. More minor re-design 
initiatives involved increasing the incidence of patient identification 
checks and ensuring multiple assessment of pregancy status 
throughout the process.  
Conclusions: This study has indicated that FMEA can be applied in the 
RT setting. Although an ever evolving process FMEA has identified 
scope for improving the RT process, strengthened the risk 
management matrix and enabled the evolution of a bespoke QC 
programme designed on the basis of prospective analysis and 
quantification of risk. Much further work is required in this area such 
as tighter specifications of RPN's, and a reduction in the beauracratic 
load however it is felt FMEA is a valuable and rapidly developing 
quality tool for radiotherapy.  
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Purpose/Objective: To investigate responses to clinically relevant 
radiotherapy regimens in new generation mouse models for BRCA1/2-
deficient breast cancer using a preclinical system for image-guided 
irradiation. 
Materials and Methods: Radiotherapy interventions were carried out 
using a small-animal dedicated Cone-Beam CT(CBCT) equipped micro-
irradiator. A dose-response (i.e. Tumor Control Probability, TCP) 
relationship was determined using various fractionated treatment 
regimens (i.e. 2Gy, 4Gy, 8Gy per fraction) in the BRCA1 model. In 
addition, radiosensitivity of the other models was determined. For this 
purpose, the tumors were measured by caliper and CBCT. Metastatic 
spread was investigated by CBCT and routine pathology of inner 
organs. We are currently harvesting residual and relapsing tumors that 
escaped radiotherapy control to determine whether these contain 
stably radioresistant cells. Similarly, tumor specimens of metastatic 
lesions are reimplanted and irradiated to determine the 
radiosensitivity. Ongoing assays are evaluating DNA damage and 
repair, epithelial-mesenchymal-transition (EMT) and gene expression 
profiling. 
Results: After a follow up of 6 months we observed a dose dependent 
TCP relationship. According to the Linear-Quadratic Model using 3Gy, 
the D50 and m were 84Gy and m=0.5, respectively (Fig). The optimal 
α/β ratio to recalculate the physical dose into a biologically 
equivalent dose (as given in 2 Gy per fraction) was 3 Gy. As expected, 
the BRCA1/2-deficient carcinomas were highly sensitive compared 
with the BRCA proficient carcinomas. In contrast, BRCA2-deficient 
tumors that had undergone EMT only responded moderately to 
radiotherapy. Despite their high sensitivity, most BRCA1/2-deficient 
carcinomas were not eradicated, and eventually relapsed (Fig). 
Although most recurrent tumors responded again to radiation, the 
response durations were shortened. Moreover, some recurrent tumors 
escaped radiotherapy control. As an alternative way to escape local 
radiotherapy control, we observed the occurrence of distance 
metastasis in about 20% of mice. 
 
  
Conclusions: Using dedicated preclinical image-guided irradiation 
techniques we present here that genetically engineered mouse models 
for BRCA1/2-deficient breast cancer are useful for the study of 
radiotherapy response. Our data strongly suggest that we may have a 
method to develop radiotherapy-resistant tumors which will be helpful 
to tackle the clinical problem of radiotherapy resistance. In 
particular, therapeutic approaches to increase radiosensitivity and 
prevent metastasis formation (e.g. PARP inhibitors) can be tested in 
these models. Moreover, we are investigating the role of hypoxia and 
DNA damage repair and targeted agents for radioresistance. Our hope 
is that these models may help to identify new therapeutic strategies 
that could guide clinical trials in the future.  
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Purpose/Objective: Determination of the main factors affecting the 
development of radiation reactions in the group of patients with 
chronic exposure. The possible impact of the absorbed dose received 
as a result of chronic radiation exposure associated with the activities 
of the plant 'Mayak', the incidence and severity of radiation reactions 
during radiotherapy. 
Materials and Methods: We have carried out a retrospective analysis 
of medical data of patients treated with external beam radiotherapy 
for solid tumors of various localizations. Study group comprised 89 
patients who had an indication on chronic radiation exposure history. 
182 patients of the control group prior were not been exposed to 
radiation. Patients of study and control groups were matched for age, 
sex, diagnosis and treatment. Assessment the frequency, severity of 
radiation reactions and complications was performed. 
Results: It was shown that the quantity of absorbed dose from chronic 
irradiation has no significant effect on the incidence and severity of 
radiation reactions. The frequency of radiation reactions did not differ 
significantly (p = 0,957): in the study group was 59.6% (53 patients), in 
the control group - 60.3% (108 patients). The distribution of reaction 
severity did not differ significantly between groups (p = 0,176). 
However, the study group was dominated by the Grade II reactions 
(64.15%), while in the control group Grade I and Grade II reactions 
distributed almost equally - 51.4% and 48.6% respectively. In some 
cases symptoms of the reactions caused the need to interrupt 
treatment. The number of breaks was significantly higher in the study 
group - 10 (11.2%) than in control - 7 patients (3.8%) (p = 0,018). 
There was statistically significant difference in the dynamics of the 
process (p =0.048), indicating a lower frequency of the positive effect 
of radiotherapy in previously irradiated patients. There were no 
statistically significant effect on the frequency of radiation reactions 
of absorbed doses to red bone marrow (CMC) (p = 0.534) and soft 
tissue (p = 0.359). The dose to the red bone marrow had no effect on 
the considered parameters: the treatment completion (p = 0.226), the 
frequency of breaks (p = 0.777), dynamics (p = 0.88). 
Conclusions: These data suggest that the main factors affecting the 
frequency of radiation reactions in cancer patients with chronic 
radiation exposure history, similar to those in patients without prior 
exposure to radiation. However, the detected changes in the severity 
of the reactions, dynamics of the process may be indicative of 
changes in radiosensitivity in patients previously exposed to chronic 
irradiation. Incorporation of these features in the radiotherapy 
planning will help to optimize a treatment plan, to reduce the 
incidence and severity of reactions, thereby improving the quality of 
life in cancer patients.  
